Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?

Early detection, prognosis, and management of IgA nephropathy (IgAN) remain a challenge. Histological examination of renal tissue still comprises the only way to confirm an IgAN diagnosis. It is of great importance to establish noninvasive diagnostic, prognostic, and predictive biomarkers that would...

Full description

Bibliographic Details
Main Authors: Karolina Marek-Bukowiec, Andrzej Konieczny, Krzysztof Ratajczyk, Wojciech Witkiewicz
Format: Article
Language:English
Published: Hindawi Limited 2018-01-01
Series:Disease Markers
Online Access:http://dx.doi.org/10.1155/2018/5205831
id doaj-5bde0e516cb047538733e14598f6f324
record_format Article
spelling doaj-5bde0e516cb047538733e14598f6f3242020-11-25T00:53:18ZengHindawi LimitedDisease Markers0278-02401875-86302018-01-01201810.1155/2018/52058315205831Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?Karolina Marek-Bukowiec0Andrzej Konieczny1Krzysztof Ratajczyk2Wojciech Witkiewicz3Regional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, PolandRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, PolandRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, PolandRegional Specialist Hospital in Wrocław, Research and Development Center, Wrocław, PolandEarly detection, prognosis, and management of IgA nephropathy (IgAN) remain a challenge. Histological examination of renal tissue still comprises the only way to confirm an IgAN diagnosis. It is of great importance to establish noninvasive diagnostic, prognostic, and predictive biomarkers that would improve the clinical care and outcome of patients suffering from IgAN. This review summarises the findings from previous mass spectrometry- (MS-) based studies dedicated to the discovery of urinary peptide profiles specific to IgAN. There is a substantial number of urinary peptides that have been discovered to date, which show promise as biomarkers of IgAN; however, all of them require further, rigorous validation in well-planned studies, involving a large number of subjects who represent diverse and numerous populations.http://dx.doi.org/10.1155/2018/5205831
collection DOAJ
language English
format Article
sources DOAJ
author Karolina Marek-Bukowiec
Andrzej Konieczny
Krzysztof Ratajczyk
Wojciech Witkiewicz
spellingShingle Karolina Marek-Bukowiec
Andrzej Konieczny
Krzysztof Ratajczyk
Wojciech Witkiewicz
Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?
Disease Markers
author_facet Karolina Marek-Bukowiec
Andrzej Konieczny
Krzysztof Ratajczyk
Wojciech Witkiewicz
author_sort Karolina Marek-Bukowiec
title Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?
title_short Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?
title_full Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?
title_fullStr Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?
title_full_unstemmed Candidate Urine Peptide Biomarkers for IgA Nephropathy: Where Are We Now?
title_sort candidate urine peptide biomarkers for iga nephropathy: where are we now?
publisher Hindawi Limited
series Disease Markers
issn 0278-0240
1875-8630
publishDate 2018-01-01
description Early detection, prognosis, and management of IgA nephropathy (IgAN) remain a challenge. Histological examination of renal tissue still comprises the only way to confirm an IgAN diagnosis. It is of great importance to establish noninvasive diagnostic, prognostic, and predictive biomarkers that would improve the clinical care and outcome of patients suffering from IgAN. This review summarises the findings from previous mass spectrometry- (MS-) based studies dedicated to the discovery of urinary peptide profiles specific to IgAN. There is a substantial number of urinary peptides that have been discovered to date, which show promise as biomarkers of IgAN; however, all of them require further, rigorous validation in well-planned studies, involving a large number of subjects who represent diverse and numerous populations.
url http://dx.doi.org/10.1155/2018/5205831
work_keys_str_mv AT karolinamarekbukowiec candidateurinepeptidebiomarkersforiganephropathywherearewenow
AT andrzejkonieczny candidateurinepeptidebiomarkersforiganephropathywherearewenow
AT krzysztofratajczyk candidateurinepeptidebiomarkersforiganephropathywherearewenow
AT wojciechwitkiewicz candidateurinepeptidebiomarkersforiganephropathywherearewenow
_version_ 1725238214676971520